MedTrace Logo

REduction of Post-Operative Urinary Retention With Tamsulosin Versus Placebo (REPOURT- P) Trial

NCT04159077 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2021-02-25

No results posted yet for this study

Summary

The purpose of this study are to determine the efficacy of tamsulosin compared to placebo in reducing post-operative urinary retention and improving other clinical outcomes in people undergoing thoracic surgery.

Conditions

  • Urinary Catheterization
  • Thoracic Surgery
  • Thoracic Epidural Analgesia

Interventions

DRUG

Tamsulosin Hydrochloride

Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily) Other names: Flomax

DRUG

Placebos

Half of the patients will be assigned to receive placebo tablets in the same manner as the active intervention. These tablets will have no effect.

Sponsors & Collaborators

Principal Investigators

  • Yaron Shargall, MD, PhD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-30
Primary Completion
2023-12-31
Completion
2023-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04159077 on ClinicalTrials.gov